Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03018418 · ClinicalTrials.gov registry record · Phase 2
Proton Therapy in Reducing Toxicity in Anal Cancer
A Phase 2 study of Anus Neoplasms, sponsored by Jordan Kharofa.
- Active
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT03018418: Active Phase 2 study of Anus Neoplasms, sponsored by Jordan Kharofa.
NCT03018418 is a Phase 2 study of Anus Neoplasms that is active but no longer recruiting, run by Jordan Kharofa. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03018418, a Phase 2 study of Anus Neoplasms, is active but no longer recruiting, sponsored by Jordan Kharofa.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine whether the amount of radiation given to the normal areas around the anal cancer can be reduced by using Proton Therapy while reducing the side effects that are seen with standard therapy.
Conditions Studied
Interventions
- DRUG Chemotherapy
- RADIATION Proton therapy
Study Locations (1)
Ohio
- UC Health - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-01-04 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 2 |
What the registry record for NCT03018418 still lists
NCT03018418 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Anus Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Chemotherapy is the first listed.
NCT03018418 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03018418 about?
NCT03018418 is a clinical study titled "Proton Therapy in Reducing Toxicity in Anal Cancer". The purpose of this research study is to determine whether the amount of radiation given to the normal areas around the anal cancer can be reduced by using Proton Therapy while reducing the side effects that are seen with standard therapy.
What is the current status of trial NCT03018418?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2017-01-04. Estimated completion is 2025-07-01.
What conditions does trial NCT03018418 study?
This clinical trial studies the following conditions: Anus Neoplasms.
What interventions are being tested in trial NCT03018418?
The interventions under investigation include: Chemotherapy (DRUG), Proton therapy (RADIATION).
Who is sponsoring clinical trial NCT03018418?
This trial is sponsored by Jordan Kharofa, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03018418 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anus Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03018418's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy